[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592422":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":32,"responsibleParty":51,"collaborators":10,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":10,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Consorci Sanitari Integral","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients hospitalized for acute heart failure",null,[12],"Diagnostic Test: Evaluation of residual congestion at discharge",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","Evaluation of residual congestion at discharge","Evaluation of residual congestion at discharge will be made using:\n\n* Clinical variables: composite congestion score calculated by summing the individual scores for orthopnoea, jugular venous distension and pedal oedema;\n* Imaging variables: non-invasive left ventricular filling pressure, number of LUS B lines and the presence of pleural effusion, Venous Excess UltraSound (VExUS) score;\n* Laboratory variables: hemoglobin and hematocrit, NT-proBNP, CA-125, ST2, troponin T, creatinine, AST, ALT, Na, K, urea, bilirubin, C-reactive protein.",[9],[20],{"name":21,"affiliation":5,"role":22},"Giosafat Spitaleri, M.D.","PRINCIPAL_INVESTIGATOR",[24,28],{"name":21,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","+34 654471303","gspitaleri@csi.cat",{"name":29,"role":25,"phone":30,"phoneExt":10,"email":31},"Roman Freixa, M.D., Ph.D.","+34 935 53 12 00","roman.freixa@csi.cat",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Complex Hospitalari Universitari Moisès Broggi","RECRUITING","Sant Joan Despí","Barcelona","08970","Spain","ES",{"type":42,"coordinates":43},"Point",[44,45],2.0574,41.36718,{"lat":45,"lon":44},[48,50],{"name":21,"role":25,"phone":49,"phoneExt":10,"email":27},"+34654471303",{"name":21,"role":22,"phone":10,"phoneExt":10,"email":10},{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100592422","evaluating-residual-congestion-at-discharge-in-acute-heart-failure-patients-100592422",false,"NCT06993220","Evaluating Residual Congestion at Discharge in Acute Heart Failure Patients","Multiparametric Assessment of Residual Congestion at Discharge in Patients With Acute Heart Failure","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Patients hospitalized for new onset heart failure or worsening heart failure defined by:\n\n  1. Symptoms classified as New York Heart Association class III or IV.\n  2. Clinical or instrumental signs of volume overload (e.g., dyspnea with evidence of pulmonary congestion on X-rays or lung ultrasound, pitting edema, and jugular venous distension).\n  3. Elevated NT-proBNP levels within the first 24 hours of admission (cutoff values: 450 ng\u002FL for patients \\\u003C 50 years; \\>900 ng\u002FL for patients aged 50-75 years; \\>1800 ng\u002FL for patients \\>75 years).\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Known diagnosis of septicemia.\n* Glomerular filtration rate \\\u003C 15 ml\u002Fmin.\n* Life expectancy \\\u003C 6 months.\n* Active myocarditis.\n* Heart transplant recipients.\n* Patients with ventricular assist devices.\n* Congenital heart diseases.\n* Moderate-to-severe liver disease (Child-Pugh B-C).\n* Patients that will not be followed up by the Heart Failure Unit.","ALL","18 Years",{"count":63,"type":64},500,"ESTIMATED","OBSERVATIONAL","Treatment of congestion is one of the main goals in patients hospitalized for acute heart failure. Nevertheless, current evidence shows that decongestion is often not achieved and that residual congestion at discharge is strongly associated with poor outcomes. While this association has been demonstrated, previous studies have primarily focused on single parameters of congestion (physical examination, biomarkers, or imaging features). The aim of the study is to assess residual congestion at discharge using a multiparametric approach and to compare the prognostic value of each evaluation strategy. Additionally, the analysis will be supported by artificial intelligence to develop a multiparametric prognostic algorithm that can provide an improved predictive model compared to standard statistical approaches.",[68,69],"Acute Heart Failure (AHF)","Congestive Heart Failure(CHF)",[71,72,73,74],"acute heart failure","residual congestion","multiparametric assessment","risk stratification","2025-07-15",{"date":77,"type":78},"2025-07-18","ACTUAL",{"date":80,"type":78},"2025-01-01",{"date":82,"type":64},"2027-01-01",{"name":5,"class":6},1]